Response to ‘It takes two to Twist’  by Sun, Shiren et al.
earlier studies had already established an important role for
hypoxia-induced TWIST1 expression.
Whereas both Yang et al. and Sun et al. observe a role for
HIF-1a in regulating TWIST1 through hypoxia-responsive
elements in the TWIST1 proximal promoter, we showed
a regulation of TWIST1 by HIF-2, the HIF-1 ortholog.
Importantly, HIF-2a induces TWIST1 expression using a
distinct intronic hypoxia-responsive element rather than
through the proximal TWIST1 promoter.3 Although we
excluded an involvement of HIF-1 in both intronic and
proximal hypoxia-responsive element regulation of TWIST1,
other studies have not addressed a role for HIF-2.
Therefore, it seems that hypoxic TWIST1 induction is
regulated by both HIF-1a and HIF-2a proteins through
distinct regulatory elements in a tissue-specific manner
(Figure 1). It is clear that the hypoxic regulation of TWIST1
plays a key role in hypoxic epithelial–mesenchymal transition
induction and metastases formation. It will be interesting
to learn the mechanistic and clinical importance of the
HIF-1- versus the HIF-2-mediated regulation of TWIST1 in
disease processes.
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We thank Vooijs et al. for their interest and comments
about our paper.1 Vooijs et al. had found that hypoxia
induces Twist1 expression in a hypoxia-inducible factor
(HIF)-2a-dependent manner and that intronic hypoxia
response elements of Twist1 are regulated by HIF-2a.2
In our study, direct transcriptional activation of Twist by
HIF-1a was found to promote epithelial-to-mesenchymal
transition (EMT) in tubular cells.3 Yang et al.4 also showed
that HIF-1a directly regulates the expression of Twist by
binding to hypoxia-responsive elements in the Twist
proximal promoter, resulting in EMT and metastastic
phenotypes. Thus, Twist may be the target gene of both
HIF-1a and HIF-2a. However, we think the role of Twist
in hypoxia-induced renal EMT and fibrosis is mediated
only by HIF-1a, not HIF-2a.
The expressions of both HIF-1a and HIF-2a are tissue-
and cell type–specific. HIF-1a is ubiquitously expressed,
whereas HIF-2a expression is more restricted. HIF-2a has
been found in hepatocytes, cardiomyocytes, glial cells, type
II pneumocytes, and endothelial cells. In addition, it has
been reported that HIF-1a and-2a are also expressed in
different renal cell populations.5 HIF-1a is mainly induced
in tubular cells as well as in proximal tubules, distal
tubules, and connecting tubes. Although HIF-2a is not
expressed in tubular cells, it is expressed in the endothelial
cells of a small subset of glomeruli and in peritubular
endothelial cells and fibroblasts. The selective induction of
HIF-1a and -2a in different types of cells in the kidney
should use different aspects of hypoxic response pathways
in a cell type–specific or temporospatial manner. It would
be interesting to further investigate the potential roles of
the HIF-2a in hypoxic kidney.
In conclusion, although hypoxic Twist induction is
regulated by both HIF-1a and HIF-2a in some specific cell
types, including cancer cells, we feel that Twist-induced
renal EMT and fibrosis under hypoxia are dominantly
mediated by an HIF-1a-dependent pathway.
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Figure 1 | Schematic representation of the TWIST1 genomic
structure and the putative hypoxia-responsive elements
(HREs) involved in TWIST1 regulation by hypoxia-inducible
factor (HIF) proteins. Exons (white boxes), the coding sequence
(gray box), and the HREs (black boxes) are shown here. Nucleotide
positions of functional HREs in the TWIST1 genomic locus bound
by HIF-1a or HIF-2a proteins in different systems are indicated
(see text for details). EMT, epithelial–mesenchymal transition.
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Cystatin C levels are unaltered in
patients with diabetes mellitus
and normal renal function
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To the Editor: In their recent article, Stevens et al.1 have
reported that factors other than glomerular filtration rate
(GFR) affect serum cystatin C (CysC) levels. Specifically,
they mentioned the impact of diabetes mellitus, which was
associated with 8.5% higher levels of CysC. However,
proteinuria was also associated with CysC and, as admitted
by the authors, diabetes and proteinuria were strongly
associated in their patient cohorts. Thus, their data did not
allow for determining the independent effects of diabetes
mellitus or proteinuria. We have previously reported GFR
data of a cohort of patients with normo-albuminuric diabetes
type I and age- and sex-matched controls.2 From this cohort,
we have selected 33 patients and 38 controls with matching
GFR (inulin clearance) and evaluated the relationship
between CysC and GFR.
At baseline, the mean GFR was 112±9ml/min per 1.73m2
and mean CysC was 0.68±0.1mg/l. In univariable regression
analysis, age (P¼ 0.016), gender (P¼ 0.001), serum albumin
(P¼ 0.001), and serum urea (P¼ 0.002) significantly influ-
enced the relationship of CysC with GFR. Diabetes was not a
predictor of this relationship (Figure 1). In multivariable
analysis age (P¼ 0.003), gender (P¼ 0.007), and serum urea
(P¼ 0.004) remained independent predictors.
In our cohort of type I diabetic patients with normal renal
function without proteinuria, we could not confirm the
influence of diabetes on the relationship between CysC
and GFR. The effect, as found by Stevens et al.,1 may be due
to the interaction with proteinuria, which was present in
the majority of their patients.
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Dividing stage 3 of chronic kidney
disease (CKD): 3A and 3B
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To the Editor: Changing the chronic kidney disease (CKD)
staging system, as proposed by Winearls and Glassock,1 could
have a negative impact on prevention. One of the hardest
tasks faced by a nephrologist is breaking the news about
imminent dialysis to an unsuspecting patient. This gets ever
more painful if early signs of kidney disease, such as a mildly
depressed glomerular filtration rate (eGFR), were somehow
uncovered in the past but the patient was reassured without
further testing and sent home only to learn otherwise at a
later date. Bad as it seems, this is a recurrent experience for
any nephrologist. Therefore, we were concerned with this
proposition to revise the Kidney Disease Outcomes Quality
Initiative (KDOQI) staging system of CKD and eliminate the
current early stages of the system. Although we recognize that
a proportion of healthy individuals may be transitorily
mislabeled as CKD patients, we believe that it is better to
raise the possibility of incipient CKD and discard it afterward
than to miss diagnosis by not looking for it. The current
staging system of CKD has been very successful in bringing
worldwide uniformity to the nomenclature and has met the
goal of raising awareness within the renal and nonrenal
medical communities to new levels. Rather than a matter of
opinion, this is a ripe area for scientific inquiry. We challenge
the renal community, as would be the case with any new
classification system, to use tools of diagnostic statistics and
to determine the predictive values of KDOQI staging within
the different categories so that we can act and inform our
patients appropriately.
However, we do not disagree that a minor review of CKD
staging may be in order. The wide range of GFR that defines
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Figure 1 |Relationship between Cystatin C levels and
glomerular filtration rate (inulin clearance). Diabetes does not
influence this relationship.
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